Searched for
PHARMEASY BOARD
Mother's Day Special: How AI, apps are empowering women to manage finances, improve health, build careerWomen are learning to keep pace with the ubiquitous apps and AI, shrugging off dependence on their kids for financial transactions, online ...- Pharmeasy founder Siddharth Shah steps down as CEOPharmeasy founder Siddharth Shah has stepped down as the chief executive to assume the role of vice chairman of the company's board. Rahul ...
- PharmEasy to formally discuss IPO plans with its board in second trySources told ET that online pharmacy startup PharmEasy could hit the bourses this year, two years after its previous attempt. The company w...
- CCI clears Ranjan Pai’s investment in PharmEasyRanjan Pai invests in PharmEasy's funding with 360 One. API Holdings board seats acquired. Rights issue resolves debt. Monthly burn reducti...
- PharmEasy CEO has three-year lock-in, Ranjan Pai to get three board seatsPai is also joining the board of PharmEasy and is expected to work with CEO Shah. He will retain the board seats as long as his holding doe...
- ETtech Explainer: What are down rounds and will they become the norm for Indian startups?A down round is when a privately held firm raises funds at a valuation lower than that ascribed in the previous round.
- PharmEasy valuation crash may not hit Thyrocare founder Velumani’s stakePharmEasy is faced with a steep cut in its valuation, with the new funding round pegging its shares at Rs 5 each compared to the Rs 50 per ...
- PharmEasy parent seeks shareholder nod to increase authorised share capitalThe board notified its shareholders about increasing the authorised share capital to Rs 3,500 crore (about $423.72 million), divided into 3...
- Exclusive: PharmEasy plans Rs 2,400-crore rights issue at 90% discount to repay loanMumbai-based epharmacy platform PharmEasy is likely to be valued at $500-600 million compared to the $5.6 billion valuation in 2021
- PharmEasy logs first ebitda profit of Rs 14 crore in April, restarts funding talksThe epharmacy held discussions with CDPQ, ADQ; convertible notes are also being discussed amid valuation corrections and markdowns.
- Exclusive | Not selling Thyrocare, will cut cash burn: PharmEasy founders to boardPharmEasy’s parent API Holdings has also delayed internal plans for a potential initial public offering (IPO) to 2025, the people privy to ...
- PharmEasy in talks to raise upto $300 million, valuation may drop by halfExisting investors will also put in $70 million, valuation at $2.5-$2.75 versus $5.4 billion of last year’s pre-IPO round. IPO is shelved f...
- PharmEasy delays IPO, targets Ebitda breakeven by next yearThe Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...
- Sebi clears PharmEasy’s Rs 6,250 crore IPOMumbai-based API Holdings had filed its draft IPO papers in November to raise Rs 6,250 crore through a sale of primary shares. Existing sha...
- PharmEasy parent company gets Sebi nod for Rs 6,250-cr public offerAPI Holdings, the parent firm of PharmEasy, has got clearance from markets regulator Securities and Exchange Board of India for the online ...
- Tata-owned 1mg, PharmEasy go offline for omnichannel presenceTata-owned 1mg is set to open its first physical store in Gurugram next month while rival PharmEasy has started to expand across the offlin...
- Exclusive: New investors in talks to join PharmEasy’s pre-IPO funding roundThe company has also finalised a secondary transaction of around $100 million in which some existing investors, such as Infosys cofounder N...
- Pre-IPO bout to value PharmEasy at $6 billionTalks on with Amansa, Blackstone, OrbiMed and others as e-pharmacy eyes IPO at $7-8 billion valuation.
- PharmEasy parent API Holdings strengthens board ahead of IPOAPI Holdings — the parent company of PharmEasy — has appointed five independent directors to its board. India's biggest online pharmacy is ...
- PharmEasy in investment talks with Naspers, TPGOnline pharmacies such as PharmEasy and 1mg have registered growth outside their core metropolitan markets by rapidly expanding into tier-2...
Load More
